|
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments
|
02 September 2015 |
|
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications
|
21 August 2015 |
|
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients
|
17 July 2015 |
|
Novartis Pharmaceuticals launches the first app for visually impaired people for use with the Apple Watch and other smart watches
|
30 June 2015 |
|
Novartis deepens its industry leading pipeline with acquisition of Spinifex Pharmaceuticals, Inc.
|
29 June 2015 |
|
Novartis highlights strong innovation momentum at its second Meet Novartis Management investor day
|
18 June 2015 |
|
Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma
|
01 June 2015 |
|
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
|
21 May 2015 |
|
Novartis accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group
|
30 March 2015 |
|
FDA approves first biosimilar ZarxioTM (filgrastim-sndz) from Sandoz
|
06 March 2015 |